<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Clinical Trials - Brain and Spine</title>
    <link rel="stylesheet" href="styles.css">
    <link rel="icon" href="favicon.ico">
    <link href="https://fonts.googleapis.com/css2?family=Roboto:wght@400;700&display=swap" rel="stylesheet">
    <style>
        body {
            font-family: 'Roboto', sans-serif;
            margin: 0;
            padding: 0;
            color: #333;
        }
        header {
            background-color: #004E25;
            color: #fff;
            padding: 1rem 0;
            text-align: center;
        }
        nav {
            background-color: #003B1A;
            padding: 0.5rem 0;
        }
        nav ul {
            list-style: none;
            margin: 0;
            padding: 0;
            display: flex;
            justify-content: center;
        }
        nav ul li {
            margin: 0 1rem;
        }
        nav ul li a {
            color: #fff;
            text-decoration: none;
            font-weight: bold;
        }
        nav ul li a:hover {
            text-decoration: underline;
        }
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 1rem;
        }
        section {
            padding: 2rem;
            margin: 2rem 0;
            border-radius: 8px;
            box-shadow: 5px 10px 15px rgba(0, 0, 0, 0.3);
        }
        section:nth-of-type(odd) {
            background-color: #f4f4f4;
        }
        section:nth-of-type(even) {
            background-color: #e0e0e0;
        }
        h2 {
            text-align: center;
            color: #004E25;
        }
        ul {
            list-style: none;
            padding: 0;
        }
        ul li {
            margin: 0.5rem 0;
        }
        ul li a {
            color: #004E25;
            text-decoration: none;
        }
        ul li a:hover {
            text-decoration: underline;
        }
		footer {
            background-color: #003B1A;
            color: #fff;
            text-align: center;
            padding: 1rem 0;
            margin-top: 2rem;
            width: 100%;
        }
    </style>
</head>
<body>
    <header>
        <h1>Clinical Trials for CNS Tumors at Rush</h1>
    </header>
    
    <nav>
        <ul>
            <li><a href="../index.html">Home</a></li>
            <li><a href="#active">Active Trials</a></li>
            <li><a href="#soon">Set to Open</a></li>
            <li><a href="#closed">Recently Closed</a></li>
			<li><a href="#abbrv">Abbreviation Glossary</a></li>
        </ul>
    </nav>

    <div class="container">
        <section id="active">
            <a href="https://www.rush.edu/clinical-trials?area=481"><h2 text-decoration: none>Currently Active Clinical Trials</h2></a>
            <ul>
                <li><a href="https://www.rush.edu/clinical-trials/post-surgical-srt-versus-start-gamma-tile-treatment-newly-diagnosed-metastatic">ROADS</a>: GammaTile Brachytherapy vs Postoperative SRS for Resected Brain Metastases</li>
                <li><a href="https://www.rush.edu/clinical-trials/observation-or-radiation-therapy-treating-patients-newly-diagnosed-grade-ii">NRG-BN003</a>: Observation vs Radiation for Completely Resected Grade 2 Meningioma</li>
				<li><a href="#">NRG-CC009</a>: Phase III Trial of SRS vs HA-WBRT for 10 or Fewer Brain Metastases in SCLC</li>
                <li><a href="#">Enzasturin</a>: Trail for Newly Diagnosed GBM Patietns with Biomarker DGM1</li>
				<li><a href="https://www.rush.edu/clinical-trials/meningioma-drug-treatment-study">FAK Inhibitor</a>: Use of  Vismodegib and FAK Inhibitor GSK2256098 for Meningioma Patients with SMO or NF2 Mutation</li>
				<li><a href="https://www.rush.edu/clinical-trials/registry-management-and-outcome-metastatic-spine-tumors">MTRON</a>: Multicenter Prospective Registry for the Management and Outcome of Metastatic Spine Tumors</li>
            </ul>
        </section>

        <section id="soon">
            <h2>Clinical Trials Set to Open Soon</h2>
            <ul>
                <li><a href="#">GESTALT</a>: Feasibility Study of Resection and Gammatile Followed by Concomitant EBRT and TMZ and Adjvuant TMZ in Newly Diagnosed GBM</li>
                <li><a href="#">NRG-BN013</a>: Phase III Trial of Single Fraction SRS vs Fractionated SRS for Intact Brain Metastases</li>
                <li><a href="#">A071701</a>: Genomically-Guided Treatment Trial in Brain Metastases</li>
				<li><a href="#">NRG-B010</a>: Phase II Study of Combination Tocilizumab, Atezolizumab, and fSRS in Recurrent GBM</li>
				<li><a href="#">CNS-201</a>: Open-Label Study of IV Berubicin in Recurrent GBM After Failure of STandard FLT</li>
			</ul>
        </section>

        <section id="closed">
            <h2>Recently Closed Clinical Trials</h2>
            <ul>
                <li><a href="#">TRIDENT / EF-32</a>: A Phase III Randomized, open-label study of Optune (TTFields) concominant with radiatino therapy and temozolomide for the treatemtn of newly diagnosed glioblastoma</li>
                <li><a href="#">NRG-BN009</a>: Phase III Trial of Salvage SRS vs SRS with HA-WBRT for Brain Metastasis Relapse (>/= 4 brain metastases/year)</li>
				<li><a href="#">NRG-CC003</a>: Randomized Phase II/III Trial of PCI with or without HA-WBRT for SCLC</li>
            </ul>
        </section>
		
		<section id="abbrv">
			<h2>Abbreviations</h2>
            <ul>
                <li>GBM - Glioblastoma</li>
                <li>SRS - Stereotactic Radiosurgery</li>
				<li>fSRS - Fractionated Stereotactic Radiosurgery</li>
                <li>TMZ - Temozolomide</li>
                <li>TTD - Tumor Treating Fields</li>
				<li>MRI - Magnetic Resonance Imaging</li>
				<li>FLT - First Line Therapy</li>
				<li>HA-WBRT - Hippocampal Avoidant Whole Brain Radiotherapy</li>
				<li>SCLC - Small Cell Lung Cancer</li>
				<li>PCI - Prophylactice Cranial Irradiation</li>
			</ul>
		</section>
    </div>


    <footer>
        <p>Â© Tatebe Lab - Radiation Oncology, Physics, Imaging, and Data Science</p>
    </footer>
</body>
</html>
